Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of NWRN.SW is 32 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell